Genéricas

The 34th National Congress of the Italian Society for the Study of Atherosclerosis (SISA) took place virtually on the 22nd of November. The Congress addressed several topics of interest in the [...]

The much-anticipated UK Genomic Health Strategy has now been published! ‘The strategy sets out an ambitious and compelling vision for how to create the most advanced genomic healthcare [...]

On the 8th October our Scientific & Medical Manager, Dr Marta Carrera, attended as a key speaker at the Spanish Familial Hypercholesterolemia (FH) Foundation Conference presenting the [...]

World Heart Day (29th September) is an international, educational, campaign day for cardiovascular disease. Not just this day, but every day, lifestyle and preventative measures to reduce the [...]

GEN inCode UK Limited the privately owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease announces today the completion of a £3.0m [...]

As part of our ongoing plan to combat the SARS-CoV-2 virus (Covid-19) and in response to the needs of our customers and collaborating health care partners, GEN inCode are now offering Covid-19 [...]

Due to the unprecedented circumstances relating to Severe Acute Respiratory Syndrome Coronavirus-2  (SARS-CoV-2 or COVID-19), some of the services of GEN inCode may be modified in accordance with [...]

London and Barcelona, February 13, 2019 The International Journal of Sciences published the results of the study “Prediction of Recurrent Pregnancy Loss by a New Thrombophilia Based Genetic Risk [...]

On September 12, 2018 GEN inCode acquired the personalized medicine service of the products Cardio inCode®, Lipid inCode®, SudD inCode® and Thrombo inCode® and the assets and know-how of the [...]